1

REPRESENTATIVE PORTFOLIO OPPORTUNITIES

This Business Overview is confidential, is exempt from registration under the Securities Act of 1933 as amended (the Securities Act), and is being furnished solely for the purpose of enabling you to consider the opportunity to ask more pertinent and up to date questions reference to the company described herein. No representation or warranty, express or implied, is made as to the accuracy or completeness of this information, and nothing contained in this overview is, or shall be relied upon as, a promise or representation. Any reproduction or distribution of this overview, in whole or in part, and any disclosure of its contents or use of any information herein for any purpose other than considering an investment in the common stock in MDCorp is prohibited. By accepting delivery of this overview, you agree to the foregoing: You should not construe the contents of this overview as legal, business or tax advice. You should consult your own attorney and tax adviser as to legal, business and tax advice. In making an investment decision, if an investment were offered at all, you must rely on your own examination and the terms of this offering documents, including the merits and risks involved. You should be aware that you may be required to bear the financial risks of the investment for an indefinite period of time. The distribution of this overview and the potential future offering or potential sale of common stock in MDCorp, if ever there were one, in certain jurisdictions may be restricted by law. Persons into whose possession this overview comes are required to be informed about and to observe any such restrictions. Except as otherwise indicated, this overview speaks as of the date of this document. Neither the delivery of this overview nor any sale of the common stock privately or publicly shall, under any circumstances, create any implication that there has been no change in our affairs after the date of this overview. Any reproduction or distribution of this document, in whole or in part, without the prior written consent of the Company, is prohibited. You should rely only on the information contained in this overview, and with the full knowledge that the contents are subject to change without notice, likely to change rapidly, and therefore should not be relied upon for investment purposes, but only as highly aspirational representative information describing what we broadly may choose to do in the future. We have not authorized anyone to provide you with information different from that contained in this overview. We may in the future be offering to sell to a limited number of direct friends and family investors to the extent that offers and sales are permitted. The information contained in this overview is accurate only as of the date of this overview, regardless of the time of delivery of this overview. The Company is under no obligation to update this overview.

Safe Harbor

3

What We do

MDCorp drives the rollup and platform foundation for MedTech companies worldwide with a special emphasis on the Asia and Pacific Rim marketplace.

MDCorp acquires what is feels is leading technology in the medical and biotech space, then works with its extensive network to develop that technology and build world class partnerships and grow the business organic to MDCorp.

MDCorp will directly or indirectly capitalize its subsidiaries in order to drive the best economics we feel are available for each technology or solution, allowing our subsidiary managers to directly fund themselves or where appropriate or where it creates more value, use equity in MDCorp to drive investment from our corporate entity.

4

Why we do it

MDCorp has long recognized that Asia is the home for more than 50% of the worlds population and yet healthcare spending per-capita remains some -75% below developed country averages.

MDCorp recognizes that novel therapeutics and world class technology development and innovation create a very high-pain environment if basic technology remains undeveloped and thus the local market perpetually underserved.

MDCorp uses its network, owned technology, distribution and brand equity to more rapidly develop med-tech and biotechnology solutions in the local market making MDCorp one of the most unique investment platforms through which we can accelerate local market product development and by extension, product distribution.

5

How we do it

SegmentGodheadforLeadershipandMarketPenetra6on

ConsolidatedBankandFinance

ConsolidatedMarke6ngandSales

CombinedMarketProwesswithMul6pleproducts

IncreasedvisibilitywithPublicPresence

FundingatsubsidiaryoratListedcompanybothpossible

6

Where we do it

*Romania *Bulgaria

*London *Greece *Shanghai

7

Portfolio opportunities under Examination

1. : (ITP) :

/

8

2. ITP drug Product Information Indication: ITP Value story: This drug has orphan designation, which

brings lower researching costs as there are only 2-3 hematology players, small studies

The true value of fostamatinib will not materialize until an FDA adcom occurs in Q4 17

Company Information Location: Non-Chinese

Development Progress Development stage: unknown

Opportunity Licensing/M&A information: Looking for licensing out,

co-development and M&A opportunities

9

3. : I(T1DM) : cell cell

2017

2013-2023I 66136

/PAB-

ENDOINSULIN1p2

10

4. Predictive autoimmune biomarkers Product Information Indication: Type 1 Diabetes (T1DM) Product Features and Advantages: It can accurately

predict the recent treatment failure caused by low insulin secretion, lack of cell or cell dysfunction. In addition, by stopping the treatment timely, it can ensure that patients still have insulin secretion. It is with smaller side effects and long-lasting efficacy

Company Information LocationNon-Chinese Year Established2017

R&D Process R&D Information: Clinical trials a year, is expected

to need more two years Intellectual Property Protection Information:

Patented

Market Opportunities

Market Assessment: The global market of diabetes will grow from

6.6 billion dollars to 13.6 billion dollars from 2013 to 2023 Efficacy Evaluation: It has not met the expectations yet Authorization/M&A:Seeking external product authorization, seeking

exclusive license agreement for PAB-ENDOINSULIN1p2, seeking partners to jointly develop predictive autoimmune monitoring derived drugs and markets

11

5. III :I(T1DM) IIT2DM : 24

2013

US/

PCT

2402020 480

12

6. A glucose-responsive insulin for type 1 and type 2 diabetes Product Information Indication: Type 1 Diabetes (T1DM) ; Type 2

Diabetes (T2DM) Product Features and Advantages:24-hour delivery

of insulin with single administrationgive those with diabetes a chance at a normal life.better protect patients against long-term diabetic complicationsvia a self-regulating system that requires no patient intervention post-dos

R&D Process

R&D Information: Under development Intellectual Property Protection Information:

Agglomerated vesicle technologyThe technology is covered by one issued US patent and one US/ PCT patent application

Market Opportunities

Market Assessment: The 24 billion market will grow to 48 billion in 2020

Authorization/M&A: Seeking for external capital injection

Company Information Location: Non-Chinese Year Established: 2013

13

7. :, : , GMP

2016

2017I

2017DFU15.8 CAGR39.3

14

8. NexGen biological drugs to accelerate wound healing Product Information Indication: treating wounds in skin and mucosa, diabetic foot ulcers Product Features and Advantages:24-hour : a novel drug delivery

system for biological drugs using lactic acid bacteria as vectors accelerated wound healing. Bacteria can be freeze-dried with maintained effect using a simple and scalable GMP-protocol. Very cost efficient system for delivery of biological drugs compared to recombinant proteins. *The lactic acid produced has antibiotic effect for wound pathogenic bacteria

Company Information Location: Non-Chinese Year Established: 2016

R&D Process R&D InformationPreclinical, will be Phase I

clinical trials in 2017

Market Opportunities

Market Assessment 2017, DFU sales are forecast to grow to $1.58 billion at a Compound Annual Growth Rate (CAGR) of 39.3% over the five-year period.

15

9.

:DR :

GLPGMP

2013

2015652023 6.9%

/

16

10. A small molecular weight lipid for diabetic retinopathy Product Information Indication: diabetic retinopathyDR Product Features and Advantages: Angiogenesis

Cytoprotective and Anti-inflammatory,GLP and GMP studies plannedproof of concept

R&D Process R&D Information ready to pre-clinical toxicity

studies Intellectual Property Protection Information:Apply

for a patent in the United States

Market Opportunities

Market Assessment 2015 market size of 6.5 billion US dollars, is expected to rise by 2023 to 6.9%

Authorization/M&A Looking for investment

Company Information Location: Non-Chinese Year Established: 2013

17

Shawn Mesaros Chief Executive Officer MDCorp 9B, Atmel Building 148 Des Voeux Road Central, Central Hong Kong +852-8199-9853 +61-(02) 8005 0887 Australia +86-18221563221 PRC Direct

18

Investor Contact